A 19-year-old Canadian man becomes the first human cured through prime gene editing after doctors corrected a rare genetic ...
Prime Medicine's application will test an FDA that has promised to speed new gene-editing treatments but has recently spurned ...
On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both ...
Prime Medicine, Inc. (NASDAQ:PRME) is among the 12 Best Genomics Stocks to Invest In. Prime Medicine, Inc. (NASDAQ:PRME) stated on December 7, 2025, that the New England Journal of Medicine has ...
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
Prime Medicine, Inc. ( PRME) TD Cowen 46th Annual Health Care Conference March 4, 2026 1:10 PM EST ...
In a new publication in Molecular Therapy, researchers from Paracelsus Medical University, Salzburg, Austria, and collaborators present a promising prime editing strategy for junctional epidermolysis ...
Hosted on MSN
LifeSci Capital initiates Prime Medicine (PRME), highlights one-and-done potential in liver and lung diseases
Prime Medicine Inc. (NASDAQ:PRME) is one of the best biotech penny stocks to buy according to analysts. On December 23, LifeSci Capital initiated coverage of Prime Medicine with an Outperform rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results